Skip to main content
SpringerLink
Log in
Book cover

Personalised Medicine pp 111–128Cite as

Can Astrocytes Be a Target for Precision Medicine?

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1007))

Abstract

Astrocytes are the most abundant non-neural cell type residing within the central nervous system (CNS) displaying tremendous heterogeneity depending on their location. Once believed to be ‘passive support cells for electrically active neurons’, astrocytes are now recognised to play an active role in brain homeostasis by forming connections with the surrounding neurons, microglia and endothelial cells. Most importantly, they provide an optimum microenvironment for functional neurons through regulation of the blood brain barrier, energy supply and removal of debris and toxic waste.

Their dysfunction has been identified as a potential contributing factor for several neurodegenerative disorders, from Alzheimer’s Disease to Amyotrophic Lateral Sclerosis.

In this chapter, we will explore the implications of astrocyte dysfunction in neurodegenerative diseases and how these cells can be used as therapeutic targets in precision medicine.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lashley T, Rohrer JD, Mead S, Revesz T (2015) Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol 41:858–881

    Article  PubMed  Google Scholar 

  2. Li W et al (2016) Neuropharmacologic approaches to restore the Brain’s microenvironment. J NeuroImmune Pharmacol 11:484–494

    Article  PubMed  Google Scholar 

  3. Renton AE et al (2012) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268

    Article  CAS  Google Scholar 

  4. Chandrasekaran A, Avci HX, Leist M, Kobolák J, Dinnyés A (2016) Astrocyte differentiation of human pluripotent stem cells: new tools for neurological disorder research. Front Cell Neurosci 10:215

    Article  PubMed  PubMed Central  Google Scholar 

  5. Parpura V, Verkhratsky A (2012) Astrocytes revisited: concise historic outlook on glutamate homeostasis and signaling. Croat Med J 53:518–528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pellerin L, Magistretti PJ (2012) Sweet sixteen for ANLS. J Cereb Blood Flow Metab 32:1152–1166

    Article  CAS  PubMed  Google Scholar 

  7. Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pr Neurol 2:679–689

    Article  CAS  Google Scholar 

  8. Rothstein JD, Martin LJ, Kungl RW (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326:1464–1468

    Article  CAS  PubMed  Google Scholar 

  9. Bruijn LI et al (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18:327–338

    Article  CAS  PubMed  Google Scholar 

  10. Rothstein JD et al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675–686

    Article  CAS  PubMed  Google Scholar 

  11. Wang DD, Bordey A (2008) The astrocyte odyssey. Prog Neurobiol 86:342–367

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Jurič DM, Kržan M, Lipnik-Stangelj M (2016) Histamine and astrocyte function. Pharmacol Res 111:774–783

    Article  CAS  Google Scholar 

  13. Clement AM et al (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (80- ) 302:113–117

    Article  CAS  Google Scholar 

  14. Haidet-Phillips AM et al (2012) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29:824–828

    Article  CAS  Google Scholar 

  15. Meyer K et al (2014) Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A 111:829–832

    Article  CAS  PubMed  Google Scholar 

  16. Ferraiuolo L et al (2011) Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134:2627–2641

    Article  PubMed  PubMed Central  Google Scholar 

  17. Heales S, Lam A, Duncan A, Land J (2004) Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 29:513–519

    Article  CAS  PubMed  Google Scholar 

  18. Abbott NJ, Rönnbäck L, Hansson E (2006) Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7:41–53

    Article  CAS  PubMed  Google Scholar 

  19. Erdő F, Denes L, de Lange E (2017) Age-associated physiological and pathological changes at the blood–brain barrier: a review. J Cereb Blood Flow Metab 37:4–24

    Article  PubMed  Google Scholar 

  20. Wang H, Eckel RH (2014) What are lipoproteins doing in the brain? Trends Endocrinol Metab 25:8–14

    Article  CAS  PubMed  Google Scholar 

  21. Halliday MR et al (2016) Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab 36:216–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Gimsa U, Mitchison NA, Brunner-Weinzierl MC (2013) Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediat Inflamm 2013

    Google Scholar 

  23. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ (2009) Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (80- ) 323:1211–1215

    Article  CAS  Google Scholar 

  24. Philips T, Rothstein J (2014) Glial cells in amyotrophic lateral sclerosis. Exp Neurol 262PB:111–120

    Article  PubMed Central  CAS  Google Scholar 

  25. Frakes AE et al (2014) Microglia induce motor neuron death via the classical NF-kB pathway in amyotrophic lateral sclerosis. Neuron 81:1009–1023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gotovac K, Hajnšek S, Pašić MB, Pivac N, Borovečki F (2014) Personalized medicine in neurodegenerative diseases: how far away? Mol Diagn Ther 18:17–24

    Article  CAS  PubMed  Google Scholar 

  27. Geser F, Lee VMY, Trojanowski JQ (2010) Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 30:103–112

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tan RH et al (2015) TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain 138:3110–3122

    Article  PubMed  Google Scholar 

  29. Cruz NF, Ball KK, Dienel GA (2010) Astrocytic gap junctional communication is reduced in amyloid-β-treated cultured astrocytes, but not in Alzheimer’s disease transgenic mice. ASN Neuro 2:e00041

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80:1778–1783

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wyss-Coray T et al (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9:453–457

    Article  CAS  PubMed  Google Scholar 

  32. Bolognesi ML, Gandini A, Prati F, Uliassi E (2016) From companion diagnostics to theranostics: a new avenue for Alzheimer’s disease? J Med Chem. acs.jmedchem.6b00151. doi:10.1021/acs.jmedchem.6b00151

  33. Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging – FDA approval of florbetapir F18 injection. N Engl J Med 367:885–887

    Article  CAS  PubMed  Google Scholar 

  34. Mason NS, Mathis CA, Klunkc WE (2013) Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Label Compd Radiopharm 56:89–95

    Article  CAS  Google Scholar 

  35. Abou-Gharbia M, Childers WE (2014) Discovery of innovative therapeutics: today’s realities and tomorrow’s vision. 2. Pharma’s challenges and their commitment to innovation. J Med Chem 57:5525–5553

    Article  CAS  PubMed  Google Scholar 

  36. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging: early progress and future directions. Lancet Neurol 14:114–124

    Article  PubMed  Google Scholar 

  37. Maruyama M et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108

    Article  CAS  PubMed  Google Scholar 

  38. Xia CF et al (2013) [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9:666–676

    Article  PubMed  Google Scholar 

  39. Villemagne VL et al (2014) In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41:816–826

    Article  CAS  PubMed  Google Scholar 

  40. Harada R et al (2016) 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer’s disease. J Nucl Med 57:208–214

    Article  CAS  PubMed  Google Scholar 

  41. Khoo SK et al (2012) Plasma-based circulating microRNA biomarkers for Parkinson’s disease. J Parkinsons Dis 2:321–331

    CAS  PubMed  Google Scholar 

  42. Miñones-Moyano E et al (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067–3078

    Article  PubMed  CAS  Google Scholar 

  43. Siege SR, MacKenzie J, Chaplin G, Jablonski NG, Griffiths L (2012) Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 39:6219–6225

    Article  CAS  Google Scholar 

  44. Dong L et al (2014) miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol 45:746–756

    Article  CAS  PubMed  Google Scholar 

  45. Denk J et al (2015) MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One 10:1–18

    Article  CAS  Google Scholar 

  46. Zou Z-Y, Liu C-Y, Che C-H, Huang H-P (2016) Toward precision medicine in amyotrophic lateral sclerosis. Ann Transl Med 4:27

    Article  PubMed  PubMed Central  Google Scholar 

  47. Butovsky O et al (2016) Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol 77:75–99

    Article  CAS  Google Scholar 

  48. Zhao Y et al (2014) Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer’s disease (AD) and in primary human neuronal-glial (HNG) cells. Mol Neurobiol 50:97–106

    Article  PubMed  CAS  Google Scholar 

  49. Parisi C et al (2016) MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ 23:531–541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lepore AC et al (2008) Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 11:1294–1301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Harrison JF et al (2007) Altering DNA base excision repair: use of nuclear and mitochondrial-targeted N-methylpurine DNA glycosylase to sensitize astroglia to chemotherapeutic agents. Glia 55:1416–1425

    Article  PubMed  PubMed Central  Google Scholar 

  52. Caiazzo M et al (2015) Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. Stem Cell Reports 4:25–36

    Article  CAS  PubMed  Google Scholar 

  53. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676

    Article  CAS  PubMed  Google Scholar 

  54. Chestkov IV, Vasilieva EA, Illarioshkin SN, Lagarkova MA, Kiselev SL (2014) Patient-specific induced pluripotent stem cells for SOD1-associated amyotrophic lateral sclerosis pathogenesis studies. Acta Nat 6:54–60

    CAS  Google Scholar 

  55. Roybon L et al (2013) Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep 4:1035–1048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Serio A et al (2013) Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A 110:4697–4702

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bucchia M et al (2015) Therapeutic development in amyotrophic lateral sclerosis. Clin Ther 37:668–680

    Article  PubMed  Google Scholar 

  58. Johnson MA, Weick JP, Pearce RA, Zhang S-C (2007) Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J Neurosci 27:3069–3077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Krencika R, Zhang S-C (2011) Directed differentiation of functional astroglial subtypes from human pluripotent stem cells. Nat Protoc 6:1710–1717

    Article  CAS  Google Scholar 

  60. Krencik R, Weick JP, Liu Y, Zhang Z, Zhang S-C (2011) Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat Biotechnol 29:528–534

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Emdad L, D’Souza SL, Kothari HP, Qadeer ZA, Germano IM (2012) Efficient differentiation of human embryonic and induced pluripotent stem cells into functional astrocytes. Stem Cells Dev 21:404–410

    Article  CAS  PubMed  Google Scholar 

  62. Liu ML et al (2013) Small molecules enable neurogenin 2 to efficiently convert human fibroblasts to cholinergic neurons. Nat Commun 4:2183

    PubMed  PubMed Central  Google Scholar 

  63. Pfisterer U et al (2011) Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A 108:10343–10348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Son E, Ichida J, Wainger B, Toma J (2011) Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9:205–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kim J et al (2011) Direct reprogramming of mouse fibroblasts to neural progenitors. PNAS 108:7838–7843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Koistinaho M et al (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10:719–726

    Article  CAS  PubMed  Google Scholar 

  67. Proschel C, Stripay JL, Shih CH, Munger JC, Noble MD (2014) Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons. EMBO Mol Med 6:504–518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Davies SJA et al (2011) Transplantation of specific human astrocytes promotes functional recovery after spinal cord injury. PLoS One 6:e17328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Das MM et al (2016) Human neural progenitors differentiate into astrocytes and protect motor neurons in aging rats. Exp Neurol 280:41–49

    Article  PubMed  Google Scholar 

  70. Kondo T et al (2014) Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports 3:242–249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Nizzardo M et al (2016) iPSC-derived LewisX+CXCR4+β1-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. Hum Mol Genet 25:3152–3163

    Article  CAS  PubMed  Google Scholar 

  72. Srinivasan K et al (2016) Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional response. Nat Commun 7:11295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Baker DJ et al (2015) Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci 9:410

    PubMed  PubMed Central  Google Scholar 

  74. Guillot F et al (2015) Transcript analysis of laser capture microdissected white matter astrocytes and higher phenol sulfotransferase 1A1 expression during autoimmune neuroinflammation. J Neuroinflammation 12:1–14

    Article  CAS  Google Scholar 

  75. Waller R et al (2016) Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role. J Neuroimmunol 299:139–146

    Article  CAS  PubMed  Google Scholar 

  76. Simpson JE et al (2011) Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotype. Neurobiol Aging 32:1795–1807

    Article  CAS  PubMed  Google Scholar 

  77. Aronica E et al (2015) Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol Dis 74:359–376

    Article  CAS  PubMed  Google Scholar 

  78. Biswas S, Holyoake D, Maughan TS (2016) Molecular taxonomy and tumourigenesis of colorectal cancer. Clin Oncol 28:73–82

    Article  CAS  Google Scholar 

  79. Wang M et al (2016) Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease. Genome Med 8:104

    Article  PubMed  PubMed Central  Google Scholar 

  80. Frangogiannis N, Biomarkers G (2012) Hopes and challenges in the path from discovery to clinical practice. Transl Res 159:197–204

    Article  PubMed  PubMed Central  Google Scholar 

  81. Dosay-Akbulut M (2016) A review on determination and future of the predictive and personalized medicine. Int J Biol 8:32–41

    Article  Google Scholar 

  82. Collins CD et al (2006) The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vasc Pharmacol 45:258–267

    Article  CAS  Google Scholar 

  83. Sajja VSSS, Hlavac N, VandeVord PJ (2016) Role of glia in memory deficits following traumatic brain injury: biomarkers of glia dysfunction. Front Integr Neurosci 10:1–9

    Article  Google Scholar 

  84. Papa L et al (2014) GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J Neurotrauma 31:1815–1822

    Article  PubMed  PubMed Central  Google Scholar 

  85. Bouvier D et al (2012) Serum S100B determination in the management of pediatric mild traumatic brain injury. Clin Chem 58:1116–1122

    Article  CAS  PubMed  Google Scholar 

  86. Shepheard SR, Chataway T, Schultz DW, Rush RA, Rogers ML (2014) The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 9:1–9

    Article  CAS  Google Scholar 

  87. Ching ASC et al (2012) Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging 3:111–119

    Article  PubMed  Google Scholar 

  88. Liu GJ et al (2014) The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol 24:631–653

    Article  CAS  PubMed  Google Scholar 

  89. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251

    Article  CAS  PubMed  Google Scholar 

  90. Chiurchiù V et al (2014) Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 233:55–63

    Article  PubMed  CAS  Google Scholar 

  91. Turkman N et al (2011) Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives. Bioorg Med Chem 19:5698–5707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Vandeputte C et al (2011) A PET brain reporter gene system based on type 2 cannabinoid receptors. J Nucl Med 52:1102–1109

    Article  CAS  PubMed  Google Scholar 

  93. Veitinger M, Varga B, Guterres SB, Zellner M (2014) Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? Acta Neuropathol Commun 2:65

    Article  PubMed  PubMed Central  Google Scholar 

  94. Poutiainen P, Jaronen M, Quintana FJ, Brownell A-L (2016) Precision medicine in multiple sclerosis: future of PET imaging of inflammation and reactive astrocytes. Front Mol Neurosci 9:1–23

    Article  Google Scholar 

  95. Gulyas B et al (2011) Activated MAO-B in the brain of alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Int 58:60–68

    Article  CAS  PubMed  Google Scholar 

  96. Droździk M, Białecka M, Kurzawski M (2013) Pharmacogenetics of Parkinson’s disease - through mechanisms of drug actions. Curr Genomics 14:568–577

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Cacabelos R (2007) Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 3:303–333

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Rascol O et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491

    Article  CAS  PubMed  Google Scholar 

  99. Foltynie T et al (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:141–144

    Article  CAS  PubMed  Google Scholar 

  100. Lin J-J, Yueh K-C, Lin S-Z, Harn H-J, Liu J-T (2007) Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson’s disease. J Neurol Sci 252:130–134

    Article  CAS  PubMed  Google Scholar 

  101. Molchadski I et al (2011) The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurol Scand 123:117–121

    Article  CAS  PubMed  Google Scholar 

  102. Strong JA et al (2006) Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 21:654–659

    Article  PubMed  Google Scholar 

  103. Clark L et al (2007) Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69:1270–1277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Lesage S et al (2011) Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease. Hum Mol Genet 20:202–210

    Article  CAS  PubMed  Google Scholar 

  105. Limpert AS, Mattmann ME, Cosford NDP (2013) Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). Beilstein J Org Chem 9:717–732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Isobe T, Tooi N, Nakatsuji N, Aiba K (2015) Amyotrophic lateral sclerosis models derived from human embryonic stem cells with different superoxide dismutase 1 mutations exhibit differential drug responses. Stem Cell Res 15:459–468

    Article  CAS  PubMed  Google Scholar 

  107. Shichinohe H et al (2004) Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res 1029:200–206

    Article  CAS  PubMed  Google Scholar 

  108. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia 58:831–838

    PubMed  Google Scholar 

  109. Yeh C, Vadhwana B, Verkhratsky A, Rodríguez JJ (2011) Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro 3:271–279

    Article  CAS  PubMed  Google Scholar 

  110. Diaz-Amarilla P et al (2011) From the cover: phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci 108:18126–18131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Schitine C, Nogaroli L, Costa MR, Hedin-Pereira C (2015) Astrocyte heterogeneity in the brain: from development to disease. Front Cell Neurosci 9:76

    Article  PubMed  PubMed Central  Google Scholar 

  112. McGivern JV, Ebert AD (2014) Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Adv Drug Deliv Rev 69–70:170–178

    Article  PubMed  CAS  Google Scholar 

  113. del Barrio L et al (2011) Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by a7 and b2* nicotinic stimulation. Toxicol Sci 123:193–205

    Article  PubMed  CAS  Google Scholar 

  114. Avior Y, Sagi I, Benvenisty N (2016) Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 17:170–182

    Article  CAS  PubMed  Google Scholar 

  115. Glajch KE et al (2016) MicroNeurotrophins improve survival in motor neuron-astrocyte co-cultures but do not improve disease phenotypes in a mutant SOD1 mouse model of amyotrophic lateral sclerosis. PLoS One 11:1–24

    Article  CAS  Google Scholar 

  116. Terrasso AP et al (2016) Human neuron-astrocyte 3D co-culture-based assay for evaluation of neuroprotective compounds. J Pharmacol Toxicol Methods 83:72–79

    Article  PubMed  CAS  Google Scholar 

  117. Al-Ali H et al (2015) Rational polypharmacology: systematically identifying and engaging multiple drug targets to promote axon growth. ACS Chem Biol 10:1939–1951

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Blackmore MG et al (2010) High content screening of cortical neurons identifies novel regulators of axon growth. Mol Cell Neurosci 44:43–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Lorenz C et al (2017) Human iPSC-derived neural progenitors are an effective drug discovery model for neurological mtDNA disorders. Cell Stem Cell:1–16. doi:10.1016/j.stem.2016.12.013

  120. Egawa N et al (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4:145ra104–145ra104

    Article  PubMed  CAS  Google Scholar 

  121. Anderl JL, Redpath S, Ball AJ (2009) A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity. J Vis Exp 27:1–6

    Google Scholar 

  122. Rinaldi F, Motti D, Ferraiuolo L, Kaspar BK (2016) High content analysis in amyotrophic lateral sclerosis. Mol Cell Neurosci. doi:10.1016/j.mcn.2016.12.001

  123. Efremova L et al (2015) Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br J Pharmacol 172:4119–4132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Ferraiuolo L et al (2016) Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A 113:E6496–E6505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Frakes AE, Braun L, Ferraiuolo L, Guttridge DC, Kaspar BK (2017) Additive amelioration of ALS by co-targeting independent pathogenic mechanisms. Ann Clin Transl Neurol 4:76–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, S10 2HQ, UK

    Chloe F. Allen, Pamela J. Shaw & Laura Ferraiuolo

Authors
  1. Chloe F. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela J. Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Ferraiuolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Ferraiuolo .

Editor information

Editors and Affiliations

  1. Krebs Institute and Sheffield Institute for Nucleic Acids, Department of Molecular Biology and Biotechnology, Firth Court, University of Sheffield, Sheffield, United Kingdom

    Sherif El-Khamisy

Rights and permissions

Reprints and permissions

Copyright information

© 2017 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Allen, C.F., Shaw, P.J., Ferraiuolo, L. (2017). Can Astrocytes Be a Target for Precision Medicine?. In: El-Khamisy, S. (eds) Personalised Medicine. Advances in Experimental Medicine and Biology, vol 1007. Springer, Cham. https://doi.org/10.1007/978-3-319-60733-7_7

Download citation

Publish with us

Policies and ethics

Search

Navigation